Pracownia Badan Klinicznych Salus
- Address
- ul. Ołtaszyńska 92c/3, 53-034 Wroclaw, Poland
Digestive System Diseases
At Pracownia Badan Klinicznych Salus researchers are evaluating innovative therapies for ulcerative colitis, aiming to improve remission rates and patient quality of life.
- Exploration of novel biologic agents for moderate‑to‑severe disease
- Integration of patient‑reported outcomes in treatment assessment
- Development of precision‑medicine approaches based on disease biomarkers
The site currently supports two active studies with a team of four investigators, contributing to advancing care for digestive health in Europe.
Immune System Diseases
Clinical investigations at the centre focus on Sjögren’s disease, testing a targeted biologic to reduce systemic activity and enhance daily functioning.
- Assessment of immune‑modulating therapies for autoimmune conditions
- Safety and tolerability profiling of new immunotherapeutics
- Long‑term monitoring of disease activity scores
With a dedicated group of investigators, the facility is contributing valuable data to the global effort of improving treatments for immune‑mediated disorders.
Eye Diseases
The research program includes studies on ocular surface disorders, such as dry eye syndrome, which often accompany systemic autoimmune diseases.
- Evaluation of anti‑inflammatory eye drops for symptom relief
- Investigation of novel lubricating formulations to protect corneal health
- Quality‑of‑life assessments for patients with chronic eye irritation
Located in Wroclaw, Poland, the site leverages its multidisciplinary expertise to address both systemic and ocular aspects of disease.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 5 of 7 therapeutic areas and 11 of 12 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 5 by active trials.
- 1Alnylam Pharmaceuticals Inc.1active
lock +4 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
No repeated partnerships found.
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 1 624 other sites in Poland
Therapeutic Area Benchmark — Poland
Select a therapeutic area to compare against other sites in Poland.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Poland
Market Share
Country: Poland
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Pracownia Badan Klinicznych Salus
lock Showing 1 of 11 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A Phase 2b, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Assess the Efficacy, Safety, and Tolerability of IMVT-1402 in Adult Participants with Primary Sjogren’s Disease with Moderate to Severe Systemic Disease Activity | Immunovant Sciences GmbH | Phase II | Recruiting | Dec 2025 | — |
IMP list
lock Showing 1 of 12 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Dazodalibep | 2 | Unknown | 2024-07-22 | 2025-05-16 |
Request feasibility information
Ask this centre about capacity, equipment and patient population.
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.